Rabies
diseaseOn this page
Also known as lyssa
Summary
Rabies (MONDO:0019173) is a disease and 81 clinical trials. Top therapeutic interventions include doxycycline anhydrous, atovaquone, and chloroquine. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 19
- Clinical trials: 81
Clinical features
Epidemiology
Prevalence records
3 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | <1 / 1 000 000 | Europe | Validated | |
| Point prevalence | 1-9 / 1 000 000 | Europe | Validated | |
| Point prevalence | <1 / 1 000 000 | United States | Not yet validated |
Signs & symptoms
Clinical features (HPO)
19 HPO clinical features (Orphanet curated; top 19 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000716 | Depression | Very frequent (80-99%) |
| HP:0000738 | Hallucinations | Very frequent (80-99%) |
| HP:0000739 | Anxiety | Very frequent (80-99%) |
| HP:0001945 | Fever | Very frequent (80-99%) |
| HP:0002014 | Diarrhea | Very frequent (80-99%) |
| HP:0002017 | Nausea and vomiting | Very frequent (80-99%) |
| HP:0002039 | Anorexia | Very frequent (80-99%) |
| HP:0002076 | Migraine | Very frequent (80-99%) |
| HP:0003401 | Paresthesia | Very frequent (80-99%) |
| HP:0003781 | Excessive salivation | Very frequent (80-99%) |
| HP:0007018 | Attention deficit hyperactivity disorder | Very frequent (80-99%) |
| HP:0100776 | Recurrent pharyngitis | Very frequent (80-99%) |
| HP:0100785 | Insomnia | Very frequent (80-99%) |
| HP:0000708 | Atypical behavior | Very frequent (80-99%) |
| HP:0001604 | Vocal cord paresis | Very frequent (80-99%) |
| HP:0100021 | Cerebral palsy | Frequent (30-79%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0001645 | Sudden cardiac death | Occasional (5-29%) |
| HP:0004372 | Reduced consciousness/confusion | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | rabies |
| Mondo ID | MONDO:0019173 |
| MeSH | D011818 |
| Orphanet | 770 |
| DOID | DOID:11260 |
| ICD-10-CM | A82 |
| ICD-11 | 854762584 |
| NCIT | C28182 |
| SNOMED CT | 14168008 |
| UMLS | C0034494 |
| MedGen | 48308 |
| GARD | 0007516 |
| MedDRA | 10037742 |
| NORD | 1644 |
| Is cancer (heuristic) | no |
Also known as: lyssa
Disease family
This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › rabies
Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, common wart, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, molluscum contagiosum, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, arbovirus infection, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 81.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 24 |
| Not specified | 18 |
| PHASE2 | 15 |
| PHASE1 | 11 |
| PHASE4 | 10 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00260351 | PHASE4 | COMPLETED | Immunogenicity and Safety of Verorab™ in Indian Population |
| NCT01137045 | PHASE4 | COMPLETED | Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG |
| NCT01173302 | PHASE4 | UNKNOWN | Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose |
| NCT01365494 | PHASE4 | COMPLETED | Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules |
| NCT02374814 | PHASE4 | COMPLETED | Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis |
| NCT02564471 | PHASE4 | COMPLETED | Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. |
| NCT05453487 | PHASE4 | UNKNOWN | Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine |
| NCT05547815 | PHASE4 | COMPLETED | Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine |
| NCT05937113 | PHASE4 | COMPLETED | Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally |
| NCT06433440 | PHASE4 | COMPLETED | Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally |
| NCT07028801 | PHASE3 | NOT_YET_RECRUITING | Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells) |
| NCT07055295 | PHASE3 | NOT_YET_RECRUITING | Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen |
| NCT07055893 | PHASE3 | NOT_YET_RECRUITING | Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen |
| NCT07275645 | PHASE3 | ACTIVE_NOT_RECRUITING | A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 Years |
| NCT07345208 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Safety and Immunogenicity of ID vs IM Rabies Vaccine |
| NCT07416110 | PHASE3 | NOT_YET_RECRUITING | Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine |
| NCT07455318 | PHASE3 | NOT_YET_RECRUITING | Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming. |
| NCT00825305 | PHASE3 | COMPLETED | Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule) |
| NCT01339312 | PHASE3 | COMPLETED | Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine |
| NCT01388985 | PHASE3 | COMPLETED | Simplifying the Rabies Pre-exposure Vaccination |
| NCT01466387 | PHASE3 | COMPLETED | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults |
| NCT01622062 | PHASE3 | COMPLETED | Immunogenicity and Safety of Verorab® in a One-week Intradermal Post-exposure Prophylaxis Regimen |
| NCT01662440 | PHASE3 | COMPLETED | Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects |
| NCT01680016 | PHASE3 | COMPLETED | A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults |
| NCT02040090 | PHASE2/PHASE3 | COMPLETED | Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects |
| NCT02491541 | PHASE3 | COMPLETED | A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects |
| NCT02545517 | PHASE3 | COMPLETED | A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. |
| NCT02912845 | PHASE3 | COMPLETED | Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies |
| NCT03965962 | PHASE3 | COMPLETED | Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults |
| NCT04127786 | PHASE3 | COMPLETED | Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults |
| NCT04478084 | PHASE3 | COMPLETED | Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland |
| NCT04594551 | PHASE3 | COMPLETED | Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland |
| NCT04644484 | PHASE3 | COMPLETED | A Phase III Clinical Study to Evaluate SYN023’s Efficacy and Safety |
| NCT05667974 | PHASE3 | UNKNOWN | A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried |
| NCT05969626 | PHASE3 | UNKNOWN | Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells) |
| NCT07357545 | PHASE3 | COMPLETED | Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried |
| NCT04270838 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG |
| NCT07055880 | PHASE2 | NOT_YET_RECRUITING | Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell) |
| NCT07168018 | PHASE2 | NOT_YET_RECRUITING | Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccine |
| NCT07445815 | PHASE2 | NOT_YET_RECRUITING | A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DOXYCYCLINE ANHYDROUS | 4 | 3 |
| ATOVAQUONE | 4 | 1 |
| CHLOROQUINE | 4 | 1 |
| PROGUANIL | 4 | 1 |
| RABIES VACCINE | 3 | 15 |
| CHLORPROGUANIL | 3 | 1 |
| RABIES IMMUNE GLOBULIN | 3 | 1 |
| SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN | 3 | 1 |
| TYPHOID VI POLYSACCHARIDE VACCINE | 3 | 1 |
| YELLOW FEVER VACCINE | 3 | 1 |
| CV-8102 | 1 | 1 |
| CHEMBL471792 | 0 | 1 |
| CHEMBL5280707 | 0 | 1 |